New York Times: There is still no proof that [Vytorin/Zetia] help patients live longer or avoid heart attacks
Front cover New York Times today on Vytorin and Zetia:
But there is still no proof that the drugs help patients live longer or avoid heart attacks. This year Vytorin has failed two clinical trials meant to show its benefits. Worse, scientists are debating whether there is a link between the drugs and cancer.